Regulations Governing Collection and Review of Vaccine Injury Compensation Fund Article 3

Vaccine manufacturers or importers should pay a certain fee as part of the Vaccine Injury Compensation Fund. When the total amount of the fund does not reach NT$150 million or exceeds NT$400 million, the fee may be adjusted by the central competent authority based on the utilization of the revenue and expenditure of the fund.The collection of the fee mentioned in the preceding paragraph shall be calculated on a per-dose basis based on the number of vaccine doses that pass the required tests. However, for vaccines procured on a special case basis for emergency reasons in accordance with Article 48-2 of the Pharmaceutical Affairs Act or Article 51 of this Act, the fee shall be calculated based on the number of doses manufactured or imported.For each dose of vaccine, the basis for the calculation and collection of the fee prescribed in the preceding paragraph is as follows:1. Severe Pneumonia with Novel Pathogens (COVID-19) vaccine: NT$22 per dose.2. Bacillus Calmette-Guerin (BCG): NT$2 per dose.3. Vaccines other than the above two: NT$1.5 per dose.The fee collected under Paragraph 1 is waived if:1. The vaccine is manufactured for export;2. The vaccine is procured by the competent authority on a special case basis to provide aid to foreign countries; or3. The vaccine is one for which a request for a fee waiver submitted on a special case basis is approved by the central competent authority.